Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F **e, F Wang, L Fu - Journal of hematology & oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Cancer therapy with antibodies
The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Z Fu, S Li, S Han, C Shi, Y Zhang - Signal transduction and targeted …, 2022 - nature.com
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …
Non‐small cell lung cancer in China
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 …
K Goto, Y Goto, T Kubo, K Ninomiya, SW Kim… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor
activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in …
activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in …
Payload diversification: a key step in the development of antibody–drug conjugates
Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …
currently combines the selectivity of monoclonal antibodies with the potency of a payload …
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …
tumors by more than their histology has been proposed, and therapies are now tailored to …
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …